



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/464539/2021

## European Medicines Agency decision P/0391/2021

of 8 September 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral for single chain urokinase plasminogen activator (scuPA) (EMEA-002896-PIP01-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

### **Disclaimer**

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**



# European Medicines Agency decision

P/0391/2021

of 8 September 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral for single chain urokinase plasminogen activator (scuPA) (EMA-002896-PIP01-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by Lung Therapeutics, Inc. on 20 October 2000 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 23 July 2021, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

**Article 1**

A paediatric investigation plan for single chain urokinase plasminogen activator (scuPA), powder for solution for injection, intrapleural use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for single chain urokinase plasminogen activator (scuPA), powder for solution for injection, intrapleural use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

This decision is addressed to Lung Therapeutics, Inc., 2600 Via Fortuna, Texas 78746 – Austin, USA.



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/PDCO/256228/2021  
Amsterdam, 23 July 2021

## Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMA-002896-PIP01-20

### Scope of the application

#### Active substance(s):

Single chain urokinase plasminogen activator (scuPA)

#### Condition(s):

Treatment of pleural effusion

#### Pharmaceutical form(s):

Powder for solution for injection

#### Route(s) of administration:

Intrapleural use

#### Name/corporate name of the PIP applicant:

Lung Therapeutics, Inc.

### Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Lung Therapeutics, Inc. submitted for agreement to the European Medicines Agency on 9 October 2020 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 1 December 2020.

Supplementary information was provided by the applicant on 19 April 2021. The applicant proposed modifications to the paediatric investigation plan.



## Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

## **Annex I**

**The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)**

## 1. Waiver

Not applicable.

## 2. Paediatric investigation plan

### 2.1. Condition:

Treatment of pleural effusion

#### 2.1.1. Indication(s) targeted by the PIP

Treatment of loculated non-draining pleural effusions

#### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

#### 2.1.3. Pharmaceutical form(s)

Powder for solution for injection

#### 2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.
Clinical studies	1	<b>Study 1</b> (LTI-001-PED1)  Open-label, single-arm, sequential-dose cohort study to assess the safety, pleural pharmacokinetics, tolerability, and efficacy of single chain urokinase plasminogen activator (scuPA) in patients from birth to less than 18 years of age for the treatment of loculated, non-draining pleural effusions.
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

### 3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By February 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes